The Effect of Testosterone on Mood and Quality of Life

NCT ID: NCT00202462

Last Updated: 2008-10-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-11-30
• Study Completion Date: 2006-11-30

Brief Summary

We hypothesize that testosterone replacement will improve mood and quality of life in older men with low testosterone and mild depression. Study subjects will receive either testosterone gel or a placebo (inactive) gel for 12 weeks. Neither the subject or the investigator will know whether they are receiving placebo or testosterone gel. At the end of the initial 12 week period, all subjects will receive testosterone gel for 12 more weeks. Mood and quality of life measures will be obtained at baseline, at the end of the double-blind phase and at the end of the extension phase (when all subjects receive testosterone.)

Detailed Description

This is a randomized, double-blind, placebo-controlled trial of testosterone replacement in older men with age-associated hypogonadism and subsyndromal depression. Men will receive either 7.5 gm/qd of testosterone gel or a placebo gel for 12 weeks. The double-blind phase will be followed by a 12 week open-label extension in which all subjects will receive 7.5 gm/qd of testosterone gel.

Procedures: Depressive symptoms will be assessed with the Hamilton Depression Rating Scale (HDRS) and the SCL-20, a 20-item self-report depression scale that has been shown to have high reliability and validity and to be sensitive to changes in depressive symptoms in outpatients in primary care settings. The short form (16 item) Endicott Quality of Life Enjoyment and Satisfaction Scale will be used to assess quality of life changes. The Medical Outcomes Study Short-Form 36 (SF-36) will be used to assess changes in functional status. Demographic information, medical history and current medications will be determined at baseline and follow up, via patient interview and chart review. Overall medical morbidity will be ascertained with the Cumulative Illness Rating Scale. All outcome measures (SCL-20, Endicott Quality of Life Scale, HDRS,SF-36) will be assessed at baseline, week 12 (end of the double-blind phase)and week 24 (end of the extension phase). Blood draws will be done at baseline, week 12 and week 24. Laboratory assays for testosterone leves at baseline, week 12 and week 24 will be performed at the same time to minimize interassay variability.

Conditions

Gonadal Disorders; Depressive Disorder; Hypogonadism

Keywords

testosterone; depression; subsyndromal depression; quality of life

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Interventions

Testosterone gel

Testosterone gel 7.5 gm qd

Intervention Type: DRUG

Other Intervention Names

Androgel

Eligibility Criteria

Inclusion Criteria

• Age: 50 or older
• Total Testosterone <=280 ng/dl
• Subsyndromal depressive disorder: either dysthymia or minor depression (per DSM IV and DSM IV appendix)

Exclusion Criteria

• PSA >=3.0
• Klinefelter's syndrome
• Prostate or breast cancer
• Hospitalized in the past month
• Obstructive BPH
• Current testosterone treatment
• Schizophrenia, bipolar disorder, dementia
• Treatment with antipsychotics or benzodiazepines
• Alcohol dependence or other substance dependence
• Suicidal or psychotic symptoms

• Minimum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

American Federation for Aging Research

OTHER

Sponsor Role: collaborator

VA Puget Sound Health Care System

FED

Sponsor Role: collaborator

Geriatric Research Education and Clinical Care

OTHER

Sponsor Role: collaborator

University of Washington

OTHER

Sponsor Role: collaborator

Solvay Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Seattle Institute for Biomedical and Clinical Research

OTHER

Sponsor Role: lead

Responsible Party

VA Puget Sound Health Care System

Principal Investigators

Molly M Shores, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington VA Puget Sound Health Care System, GRECC

References

Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009 Jul;70(7):1009-16. doi: 10.4088/jcp.08m04478.

Reference Type: DERIVED

PMID: 19653976 (View on PubMed)

Other Identifiers

AFAR: A02034

Identifier Type: -

Identifier Source: secondary_id

Solvay:UMD-02-097

Identifier Type: -

Identifier Source: secondary_id

RDIS 0004

Identifier Type: -

Identifier Source: org_study_id